EyePoint Announces Pricing of Public Offering

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $12.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 1,500,000 shares of its common stock at a price to the public of $11.999 per each pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the shares of common stock and pre-funded warrants are being sold by EyePoint. The closing of the offering is expected to occur on or about October 16, 2025, subject to the satisfaction of customary closing conditions. In addition, EyePoint has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of EyePoint’s common stock at the public offering price, less underwriting discounts and commissions.